Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 14/20 | 0.37 |
| ▸ | JAK2 | O60674 | 11/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17631637 | 0.86 | USP30 (0.44) | TBK1JAK2GPR119USP30 | |
| SCHEMBL17631639 | 0.86 | USP30 (0.44) | TBK1JAK2GPR119USP30 | |
| SCHEMBL20934896 | 0.84 | GPR119 (0.40) | TBK1JAK2GPR119 | |
| SCHEMBL24904180 | 0.80 | USP30 (0.46) | TBK1JAK2GPR119USP30 | |
| SCHEMBL17630409 | 0.77 | TBK1 (0.44) | TBK1JAK2GPR119USP30 | |
| SCHEMBL17630410 | 0.77 | TBK1 (0.44) | TBK1JAK2GPR119USP30 | |
| SCHEMBL23639481 | 0.76 | USP30 (0.46) | GPR119USP30 | |
| SCHEMBL20935188 | 0.76 | GPR119 (0.41) | TBK1JAK2GPR119 | |
| SCHEMBL17645042 | 0.76 | TBK1 (0.43) | TBK1JAK2GPR119USP30 | |
| SCHEMBL20934771 | 0.75 | TBK1 (0.40) | TBK1JAK2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2023-01-19 | — | — | US | disclosed |
| WO-2019079373-A1 | PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | DTYMK, TBKBP1, NFKBIA | TBK1 4/4885JAK2 1021/4885GPR119 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.